FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236050471> ?p ?o ?g. }

• W4236050471 endingPage "2814" @default.
• W4236050471 startingPage "2814" @default.
• W4236050471 abstract "Abstract Bone metastases are common and count 30-70% of metastases in breast, lung, and bladder cancer, and 80% of multiple myeloma patients have bone disease. Despite recent progress in cancer treatment, bone metastases remain incurable. Novel immunotherapies have the potential to cure also bone metastatic disease. Here we have established and validated syngeneic models with a focus on bone metastasis that could be used in preclinical efficacy studies. Syngeneic models were established for breast (4T1-GFP), multiple myeloma (5TGM1), bladder (MBT-2) and lung cancer (KLN-205). The cells were inoculated into systemic circulation (4T1 intracardially and 5TGM1 into tail vein) or bone marrow (MBT-2 and KLN-205). In the 4T1 model, tumor burden was assessed by ex vivo GFP imaging and in the 5TGM1 model by measuring serum IgG2b paraprotein levels during the study. Tumor-induced bone changes were followed by X-ray imaging in all models. Hind limbs were analyzed by histology and immunohistochemistry for tumor-infiltrating lymphocytes (TILs). The effects of standard-of-care compounds were assessed in the 4T1 (cyclophosphamide, 100 mg/kg or zoledronic acid, 0.1 mg/kg) and 5TGM1 (bortezomib, 1 mg/kg) models. The effect of anti-PD-1 treatment (200 µg/dose) was evaluated in the MBT-2 model. In the 4T1 model, osteolytic bone lesions formed within 13 days. In addition to bone metastases, about 50% of the mice had metastases in lungs, ovaries, kidneys and adrenal glands based on GFP imaging. Cyclophosphamide decreased the tumor burden and the area of osteolytic bone lesions. Zoledronic acid decreased the osteolytic lesion area but had no effect on tumor burden. Low number or no TILs were observed. In the 5TGM1 model, osteolytic lesions were observed and the study was ended at day 35. Metastases in ovaries, kidneys and adrenal glands were observed in about 30% of the mice. Bortezomib decreased serum paraprotein compared to vehicle treated mice. In both models, cachexia and paraplegia were occasionally observed. Moderate number of CD3+ TILs were observed in the tumors. In the intratibial MBT-2 and KLN-205 models, large osteolytic lesions were observed within 25 days, and in the KLN-205 model also lung metastases were observed. Anti-PD-1 treatment decreased osteolytic tumor area in the MBT-2 model. Moderate number of CD3+ and low number of CD4+ and CD8+ TILs were observed in the tumors growing in bone and also in the lung metastases. A high incidence of bone metastases was observed in all models. The use of systemic models allows studying the effects of test compounds in prevention or treatment of metastases. Intratibial models can be used when the primary interest is in tumor growth in bone microenvironment. Mimicking the clinical situation, none of the SOC compounds could prevent tumor growth completely, and therefore combination therapies are warranted for better overall efficacy. Citation Format: Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Arne Scholz, Jenni Bernoulli. Systemic and local bone metastasis models for immuno-oncology drug development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2814." @default.
• W4236050471 created "2022-05-12" @default.
• W4236050471 creator A5013170089 @default.
• W4236050471 creator A5030057178 @default.
• W4236050471 creator A5034825484 @default.
• W4236050471 creator A5054563217 @default.
• W4236050471 creator A5056100150 @default.
• W4236050471 creator A5069690323 @default.
• W4236050471 date "2019-07-01" @default.
• W4236050471 modified "2023-09-27" @default.
• W4236050471 title "Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development" @default.
• W4236050471 doi "https://doi.org/10.1158/1538-7445.am2019-2814" @default.
• W4236050471 hasPublicationYear "2019" @default.
• W4236050471 type Work @default.
• W4236050471 citedByCount "0" @default.
• W4236050471 crossrefType "journal-article" @default.
• W4236050471 hasAuthorship W4236050471A5013170089 @default.
• W4236050471 hasAuthorship W4236050471A5030057178 @default.
• W4236050471 hasAuthorship W4236050471A5034825484 @default.
• W4236050471 hasAuthorship W4236050471A5054563217 @default.
• W4236050471 hasAuthorship W4236050471A5056100150 @default.
• W4236050471 hasAuthorship W4236050471A5069690323 @default.
• W4236050471 hasBestOaLocation W42360504711 @default.
• W4236050471 hasConcept C121608353 @default.
• W4236050471 hasConcept C126322002 @default.
• W4236050471 hasConcept C142724271 @default.
• W4236050471 hasConcept C143998085 @default.
• W4236050471 hasConcept C2776169692 @default.
• W4236050471 hasConcept C2776326535 @default.
• W4236050471 hasConcept C2776364478 @default.
• W4236050471 hasConcept C2776541429 @default.
• W4236050471 hasConcept C2776694085 @default.
• W4236050471 hasConcept C2776755627 @default.
• W4236050471 hasConcept C2777783956 @default.
• W4236050471 hasConcept C2779013556 @default.
• W4236050471 hasConcept C2780007613 @default.
• W4236050471 hasConcept C71924100 @default.
• W4236050471 hasConceptScore W4236050471C121608353 @default.
• W4236050471 hasConceptScore W4236050471C126322002 @default.
• W4236050471 hasConceptScore W4236050471C142724271 @default.
• W4236050471 hasConceptScore W4236050471C143998085 @default.
• W4236050471 hasConceptScore W4236050471C2776169692 @default.
• W4236050471 hasConceptScore W4236050471C2776326535 @default.
• W4236050471 hasConceptScore W4236050471C2776364478 @default.
• W4236050471 hasConceptScore W4236050471C2776541429 @default.
• W4236050471 hasConceptScore W4236050471C2776694085 @default.
• W4236050471 hasConceptScore W4236050471C2776755627 @default.
• W4236050471 hasConceptScore W4236050471C2777783956 @default.
• W4236050471 hasConceptScore W4236050471C2779013556 @default.
• W4236050471 hasConceptScore W4236050471C2780007613 @default.
• W4236050471 hasConceptScore W4236050471C71924100 @default.
• W4236050471 hasIssue "13_Supplement" @default.
• W4236050471 hasLocation W42360504711 @default.
• W4236050471 hasOpenAccess W4236050471 @default.
• W4236050471 hasPrimaryLocation W42360504711 @default.
• W4236050471 hasRelatedWork W2046478485 @default.
• W4236050471 hasRelatedWork W2047282220 @default.
• W4236050471 hasRelatedWork W2108573782 @default.
• W4236050471 hasRelatedWork W2182724507 @default.
• W4236050471 hasRelatedWork W2333447821 @default.
• W4236050471 hasRelatedWork W2466056336 @default.
• W4236050471 hasRelatedWork W2496185278 @default.
• W4236050471 hasRelatedWork W2765166154 @default.
• W4236050471 hasRelatedWork W2994772316 @default.
• W4236050471 hasRelatedWork W4376106075 @default.
• W4236050471 hasVolume "79" @default.
• W4236050471 isParatext "false" @default.
• W4236050471 isRetracted "false" @default.
• W4236050471 workType "article" @default.